ERCC1 and other markers for stratification of non-small cell lung cancer patients (ERCC1 AND OTHER MARKERS FOR STRATIFICATION OF NON-SMALL CELL LUNG CANCER PATIENTS)

摘要

The proteomic data is used to predict the treatment outcome for cisplatin / pemetrexed therapy of NSCLC. In particular, ERRC1 can be used as a binary marker in which the presence or absence of a protein is measured by mass spectrometry, and additional proteins can serve as additional predictive markers, particularly for prediction of PFS.